预约演示

更新于：2025-05-16

Decitabine

地西他滨

更新于：2025-05-16

概要

基本信息

药物类型

小分子化药

别名

2'-deoxy-5-azacytidine、4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one、4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one

+ [19]

靶点

DNMT1

作用方式

抑制剂

作用机制

DNMT1抑制剂(DNA（胞嘧啶-5）-甲基转移酶-1抑制剂)

治疗领域

肿瘤血液及淋巴系统疾病其他疾病+ [2]

在研适应症

难治性贫血难治性贫血伴原始细胞过多慢性粒单核细胞白血病+ [21]

非在研适应症

急性红细胞白血病急性巨核细胞白血病急性单核细胞白血病+ [26]

原研机构

Eisai Co., Ltd.

在研机构

Merck Sharp & Dohme Corp.

Otsuka America Pharmaceutical, Inc.

Astex Pharmaceuticals, Inc.

+ [9]

非在研机构

Cephalon, Inc.Janssen LP

Teva Pharmaceutical Industries Ltd.

+ [9]

权益机构

Janssen Pharmaceuticals, Inc.

Janssen Korea Ltd.MGI PHARMA, Inc.

+ [5]

最高研发阶段批准上市

首次获批日期

美国 (2006-05-02),

难治性贫血伴原始细胞过多难治性贫血慢性粒单核细胞白血病+ [2]

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C8H12N4O4

InChIKeyXAUDJQYHKZQPEU-KVQBGUIXSA-N

CAS号2353-33-5

关联

446

项与地西他滨相关的临床试验

NCT03184935

/ Suspended临床1/2期

Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)

The purposes of the study is to determine the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating Myelodysplastic Syndrome patients.

开始日期2025-12-31

申办/合作机构

圣释（北京）生物工程有限公司

NCT06474663

/ Not yet recruiting临床1期IIT

A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating with Decitabine in Pediatric Relapsed and Refractory Acute Leukemias

To find the recommended dose of the drug combination cladribine, cytarabine, decitabine, and sorafenib in participants with relapsed/refractory AML, MPAL, and ALAL.

开始日期2025-12-31

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT06928662

/ Not yet recruiting临床1/2期IIT

Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study

This phase I/II trial studies the safety, side effects, and best dose of decitabine in combination with fludarabine, cytarabine, filgrastim, and idarubicin (FLAG-Ida) and total body irradiation (TBI) followed by a donor stem cell transplant in treating adult patients with cancers of blood-forming cells of the bone marrow (myeloid malignancies) that are at high risk of coming back after treatment (relapse). Cancers eligible for this trial are acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. The FLAG-Ida regimen consists of the following drugs: fludarabine, cytarabine, filgrastim, and idarubicin. These are chemotherapy drugs that work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Filgrastim is in a class of medications called colony-stimulating factors. It works by helping the body make more neutrophils, a type of white blood cell. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. TBI is radiation therapy to the entire body. Giving chemotherapy and TBI before a donor peripheral blood stem cell (PBSC) transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When the healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets. Giving decitabine in combination with FLAG-Ida and TBI before donor PBSC transplant may work better than FLAG-Ida and TBI alone in treating adult patients with myeloid malignancies at high risk of relapse.

开始日期2025-09-01

申办/合作机构

Fred Hutchinson Cancer Research Center

100 项与地西他滨相关的临床结果

登录后查看更多信息

100 项与地西他滨相关的转化医学

登录后查看更多信息

100 项与地西他滨相关的专利（医药）

登录后查看更多信息

9,500

项与地西他滨相关的文献（医药）

2025-12-31·Hematology

Efficacy and safety of decitabine combined with arsenic trioxide in elderly high-risk myelodysplastic neoplasm patients: a retrospective study

Article

作者: Yang, Jianzhong

OBJECTIVES:

Elderly patients with high-risk myelodysplastic neoplasm (MDS) face poor outcomes with limited treatment options, often progressing to acute myeloid leukemia (AML). This study investigates the efficacy and safety of combining decitabine (DAC) with arsenic trioxide (ATO) as a novel therapeutic approach.

METHODS:

A retrospective analysis was conducted on 120 elderly high-risk MDS patients, with 52 receiving ATO-DAC (ATO-DAC group) and 68 receiving DAC monotherapy (DAC group). Treatment outcomes were assessed through overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Adverse events were recorded and compared between the two groups.

RESULTS:

The ATO-DAC group demonstrated a significantly higher ORR of 78.85% compared to 52.94% in the DAC group (P = 0.026). Median PFS was 7.5 months for the ATO-DAC group versus 5.0 months for the DAC group (P = 0.021), and median OS was 14.5 months compared to 11.5 months, respectively (P = 0.034). Although adverse events were more frequent in the ATO-DAC group, the safety profile remained manageable. These findings suggest that the ATO-DAC combination provides superior efficacy compared to DAC monotherapy.

DISCUSSION:

The combination of DAC and ATO offers a promising and innovative treatment option for elderly high-risk MDS patients, enhancing response rates and survival outcomes while maintaining a manageable safety profile.

CONCLUSION:

This study underscores the clinical relevance of this regimen, warranting further investigation in prospective trials.

2025-12-31·Hematology

Identification of t(X;1)(q28;q21) generating a novel GATAD2B::MTCP1 gene fusion in CMML and its persistence during progression to AML

Article

作者: Chen, Yu ; Zhu, Yi-yan ; Liu, Yi-zi ; Hou, Chun-xiao ; Zhang, Zhi-yu ; Chen, Su-ning ; Wang, Qian ; Zhang, Feng-hong

OBJECTIVE:

Hematological malignancies often involve chromosomal translocations and fusion genes that drive disease progression. While MTCP1 is well-known in T-cell prolymphocytic leukemia (T-PLL), its role in myeloid neoplasms is less understood. This report presents the first identification of the t(X;1)(q28;q21) translocation leading to the GATAD2B::MTCP1 fusion in acute myeloid leukemia (AML) transformed from chronic myelomonocytic leukemia (CMML).

METHODS:

The karyotypes were described according to the International System for Human Cytogenetic Nomenclature 2009. We performed targeted next-generation sequencing (NGS) on a panel of 172 genes commonly mutated in hematological malignancies (Supplemental Table 1), using an Illumina platform. RNA sequencing was conducted on total RNA extracted from bone marrow, also using the Illumina platform. The GATAD2B::MTCP1 fusion gene was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) and Sanger sequencing, with specific primers for the fusion transcript (GATAD2B-F: CCTCTTTTTTTCGACGCC; MTCP1-R: ACTGAGCACAACACTTACGC).

RESULTS:

The GATAD2B::MTCP1 fusion results from a breakpoint on 1q21 within GATAD2B exon 1 and Xq28 within MTCP1 exon 2. The patient with the GATAD2B::MTCP1 fusion exhibited disease progression from CMML to AML. Despite achieving initial remission with venetoclax-based therapy and allo-HSCT, the patient relapsed and died.

CONCLUSIONS:

We propose that the GATAD2B::MTCP1 fusion upregulates MTCP1 expression rather than generating a fusion protein, thereby contributing to transformation and relapse in AML. Further investigations are needed to elucidate the precise role of this fusion event in myeloid malignancies.

2025-07-01·BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

CRISPR/Cas9-directed epigenetic editing in colorectal cancer

Review

作者: Gupta, Manoj Kumar ; El-Rayes, Bassel F ; Vadde, Ramakrishna ; Moazzam-Jazi, Maryam ; Nagaraju, Ganji Purnachandra ; Gouda, Gayatri

Colorectal cancer (CRC) remains a leading cause of cancer-related illness and death worldwide, arising from a complex interplay of genetic predisposition, environmental influences, and epigenetic dysregulation. Among these factors, epigenetic modifications-reversible and heritable changes in gene expression-serve as crucial regulators of CRC progression. Understanding these modifications is essential for identifying potential biomarkers for early diagnosis and developing targeted therapeutic strategies. Epigenetic drugs (epidrugs) such as DNA methyltransferase inhibitors (e.g., decitabine) and bromodomain inhibitors (e.g., JQ1) have shown promise in modulating aberrant epigenetic changes in CRC. However, challenges such as drug specificity, delivery, and safety concerns limit their clinical application. Advances in CRISPR-Cas9-based epigenetic editing offer a more precise approach to modifying specific epigenetic markers, presenting a potential breakthrough in CRC treatment. Despite its promise, CRISPR-based epigenome editing may result in unintended genetic modifications, necessitating stringent regulations and safety assessments. Beyond pharmacological interventions, lifestyle factors-including diet and gut microbiome composition-play a significant role in shaping the epigenetic landscape of CRC. Nutritional and microbiome-based interventions have shown potential in preventing CRC development by maintaining intestinal homeostasis and reducing tumor-promoting epigenetic changes. This review provides a comprehensive overview of epigenetic alterations in CRC, exploring their implications for diagnosis, prevention, and treatment. By integrating multi-omics approaches, single-cell technologies, and model organism studies, future research can enhance the specificity and efficacy of epigenetic-based therapies. Shortly, a combination of advanced gene-editing technologies, targeted epidrugs, and lifestyle interventions may pave the way for more effective and personalized CRC treatment strategies.

269

项与地西他滨相关的新闻（医药）

2025-05-04

·生物制品圈

双靶点 CAR-T 的四种策略及其优缺点

CAR-T 细胞疗法在多种血液系统恶性肿瘤的治疗中显示出巨大的希望，包括非霍奇金淋巴瘤 (NHL) 和急性淋巴细胞白血病 (ALL)，但原发性难治性或复发性疾病是一个相对常见的现象。失败的原因很复杂，可能包括 T 细胞功能障碍、肿瘤微环境 (TME) 引起的免疫抑制、高肿瘤负荷和抗原逃逸等。其中抗原逃逸 (靶抗原表达缺失或下调) 是侵袭性 B 细胞恶性肿瘤患者耐药的主要机制，其机制也有多种，包括选择预先存在的抗原阴性克隆、抗原表达减少、获得突变、剪接位点变异、谱系转换介导的抗原丢失 (通常发生于有特定基因组异常 [如 KMT2A 重排] 的患者) 和表面抗原呈递失败。当然，这些机制通常是同时发生的。对于抗原逃逸，理论上可以通过给予靶向多抗原的多靶点 CAR-T 来克服这一机制，临床前数据也显示双靶点 CAR-T 细胞疗效优于单靶点 CAR-T 细胞，这些为具有两种或两种以上抗原特异性的产品 (如 CD19 和 CD20、CD19 和 CD22、CD19 和 BCMA 等) 的开发铺平了道路。双靶点 CAR-T 细胞的治疗策略主要有如下四种：• 单靶点 CAR-T 细胞的联合给药：包括生产两种单独的 CAR-T 细胞，并在短时间内给药。• 共转导 CAR-T 细胞：将 T 细胞共转导两个单独的病毒载体，每个载体编码不同的 CAR。需要生产一次 CAR-T 细胞，但包含两个单独的载体。• 双顺反子 CAR-T 细胞：使用编码两种不同 CAR 的单一载体生产一种 CAR-T 细胞。• 串联或环状 CAR-T 细胞：使用单一载体生产一种 CAR-T 细胞，该载体可编码具有两个不同单链可变片段 (scFv) 的单个 CAR。串联结构由一个 scFv 的 VL-VH 序列与第二个 scFv 的 VL-VH 序列直接连接组成（经典串联），而在环结构中，一个 scFv 的 VL 和 VH 序列被另一个 scFv 的 VL-VH 分离。相关数据见下表，原文有部分研究的详细介绍（10.1111/ bjh.19348）。事实上，四种策略均有自身的优缺点，具体如下。单靶点 CAR-T 细胞的联合给药合并或组合给予两种不同的 CAR-T 细胞是实现双靶点的最简单选择，特别是当两种 CAR-T 细胞都有成熟数据时，但它也是最昂贵的策略，因为每例患者需要两个完整且独立的制造流程。两种药物制成后，可混合使用并一起给药 (一次输注）或单独给药（两次输注）。此外，两次给药可以几乎连续发生 (即同一天或第二天），也可以相隔几个月。如果两次给药间隔太远，可能需要重复进行清淋化疗。共转导 CAR-T 细胞共转导需要使用两种不同的病毒载体进行单细胞制造过程，虽然操作相对简单，但由于使用的是两种载体而非一种载体，因此比传统的 CAR-T 细胞制造成本更高，并且最终产品存在一定程度的异质性。此策略的关键特征在于，所得细胞产物含有以下四种细胞群的混合物：(i) 具有一种抗原特异性的细胞；(ii) 具有另一抗原特异性的细胞；(iii) 具有两种抗原特异性的细胞；(iv) 未转导的细胞。在共转导的 CAR-T 细胞的制造过程中，由于 CAR 表达所需的细胞资源的竞争和/或其中一个细胞群的潜在优先扩增，存在着扭曲（skewed）转导和/或 CAR 群失衡的风险，而 CAR 群的不平衡可能会影响最佳双靶点的实现。与双顺反子盒（bicistronic cassette）相比，共转导通常可增强 CAR 表达，这是其优势之一。双顺反子 CAR-T 细胞在同一个 T 细胞中实现两个 CAR 双重表达的一个简单方法是使用包含双顺反子盒的单个载体。双顺反子载体包含两个基因，每个基因编码一个独特的 CAR，由一个「自裂解」肽分隔，能够平行共表达两个独立的 CAR，比例为 1:1。这种方法比联合给药或联合转导更简单、更便宜，因为每例患者只需要一个细胞产生和一个载体；且与共转导相比，双顺反子盒的产物更均一，因为所有转导的 T 细胞可在 T 细胞膜上表达两种 CAR。但这些载体需要更长的序列来编码两个完整的 CAR 分子，可能损害病毒包装（packaging），降低转导效率和破坏 CAR 表达。串联 CAR-T 细胞串联 CAR 由编码具有两个配体结合结构域的嵌合受体的单个载体产生，具有很多优点。与双顺反子 CAR 相比，结构尺寸明显更小，能够实现更好的包装。此外，它只需要一个载体，双 CAR-T 细胞产物更均一，并防止一个 CAR 相对于另一个 CAR 的优势。其缺点在于，串联 CAR 的最佳设计尚不明确，可能因使用的 scFv、靶向抗原的密度和靶向表位与 T 细胞膜的接近程度而异。很多参数都会影响 CAR 的效力，如 scFv 的顺序；每个 scFv 的 VH 和 VL 排列；VH 和 VL 之间或两个 scFv 之间的连接体长度；连接体的刚性。因此需要复杂的结构优化，包括多个 CAR 结构的生成和实证测试。在靶向 CD22 时串联 CAR 优化尤为重要，CD22 是一种低密度表达的抗原，高度糖基化，具有实质性的大小和刚性，可能损害免疫突触。总结尽管 CAR-T 细胞疗法的出现显著改善了 R/R ALL 和 NHL 患者的预后，但仍有相当比例的患者复发和死于疾病进展。这一现状促使了大量旨在靶向多抗原 (例如 CD19 和 CD20 或 CD22) 的新策略，旨在减轻抗原丢失或下调且不增加过度毒性。双靶点 CAR-T 可以通过多种手段实现，包括从简单的两种不同产品的联合给药到更复杂的双顺反子盒或串联 CAR 的设计。到目前为止，没有确凿的证据表明这些新型产品具有显著不同的毒性特征，但也没有证据表明其中一种策略优于其他策略，甚至没有证据表明双靶点优于单靶点，但抗原丢失已部分减少。部分双靶点 CAR-T 已与表观遗传学药物 (如地西他滨) 或检查点抑制剂 (如帕博利珠单抗和替雷利珠单抗) 联用，显示出有前景的疗效，且不增加毒性。其他组合包括常规 CD19 CAR-T 联合其他药物 (如抗 CD19 单克隆抗体 tafasitamab、双特异性单克隆抗体和抗体药物偶联物)。双靶点 CAR-T 的缺陷可能包括：(i) 未解决除抗原逃逸之外的其他耐药机制；(ii) 大多数临床试验随访不足；(3) 产品间异质性大，包括不同的额外靶点 (CD20、CD22 和其他)；(iv) 由于低传导效率和大尺寸的双顺反子和串联载体，导致需要复杂的制备优化。人们仍在寻找治疗 B 细胞恶性肿瘤的最佳产品和/或组合，但仍缺乏随机临床试验形式的明确证据 (但这正是人们热切期待的)。参考文献：Brillembourg H, Martínez-Cibrián N, Bachiller M, Alserawan L, Ortiz-Maldonado V, Guedan S, et al. The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies. Br J Haematol. 2024;00:1–11. https://doi.org/10.1111/ bjh.19348识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

细胞疗法免疫疗法ASH会议

2025-04-30

·ioncology

许兰平教授：聚焦全程管理，2025 CSCO造血干细胞移植治疗血液系统疾病指南更新亮点丨2025 CSCO指南会

点击蓝字关注我们编者按：2025年4月18日-19日，由中国临床肿瘤学会（CSCO）和北京市希思科临床肿瘤学研究基金会联合主办的2025 CSCO指南会在济南山东大厦隆重召开。在本次大会上，北京大学人民医院许兰平教授，针对2025 CSCO造血干细胞移植治疗血液系统疾病指南的更新内容进行了深入解读。《肿瘤瞭望-血液时讯》特整理课件精粹，以飨读者。异基因造血干细胞移植（allo-HSCT）是治疗白血病、骨髓增生异常综合征（MDS）、多发性骨髓瘤（MM）、非霍奇金淋巴瘤（NHL）及重型再生障碍性贫血（SAA）等疾病的重要根治手段。随着单倍型移植“北京方案”的建立并在全国范围内推广，allo-HSCT进入“人人皆有供者”的新时代，推动我国移植病例数量持续快速增长。2025版指南立足中国本土的临床实践与科研成果，秉持与时俱进的前瞻视角，从多个方面进行了更新，充分体现持续优化与规范化的发展方向。异基因造血干细胞移植01适应证及时机在异基因造血干细胞移植治疗急性髓系白血病、急性淋巴细胞白血病、慢性髓系白血病、骨髓增生异常综合征、其他B细胞淋巴瘤、T细胞淋巴瘤的适应证中均删去了“≤65岁”的限制。新增“异基因造血干细胞移植治疗地中海贫血的适应证”，具体见下表。02患者及供者评估在患者评估中新增“地中海贫血内容”。03预处理方案在标准清髓性（MAC）预处理中删除了AA部分。新增“地中海贫血移植预处理内容”，见下表。04急性移植物抗宿主病（aGVHD）在aGVHD一线治疗的Ⅱ级推荐中，增加“也可考虑甲泼尼龙1 mg/(kg·d)联合低剂量MTX或低剂量芦可替尼(1B类)”。05慢性移植物抗宿主病（cGVHD）在cGVHD预防的Ⅱ级推荐中，删去了“ATG+PT/CY(2B类)”。在cGVHD的诊断中，新增“眼部GVHD诊断内容”，见下表。在cGVHD一线治疗的Ⅱ级推荐中，删去了“泼尼松+奥法妥木单抗(2B类)”和“泼尼松+伊布替尼(ibrutinib)(2B类)”。在cGVHD二线治疗的Ⅰ级推荐中增加“甲磺酸贝舒地尔(2A类)”，Ⅱ级推荐中增加“西罗莫司(2A类)”和“艾克利单抗(2A类)”，Ⅲ级推荐中增加“本外光分高置换术(ECP)（2C类）”，见下表。新增“cGVHD的患者报告结局评估内容”，见下表。06真菌感染防治在治疗药物的I级推荐中增加“艾沙康唑”，见下表。07病毒感染防治在HBV再激活/感染防治中，增加“干扰素治疗”的Ⅲ级推荐，见下表。08复发防治针对ALL移植后复发的预防，在预处理方案调整的Ⅲ级推荐中，增加“西达本胺联合BUCY预处理方案改善T-ALL/LBL的移植后生存（2B类）”；在靶向药物治疗中，将“Ph-ALL:移植前MRD阳性用贝林妥欧单抗桥接”由Ⅲ级（2B类）推荐调整为Ⅱ级（2A类）推荐，并在Ⅲ级推荐中增加“②移植前CAR-T桥接(MRD阳性)”，见下表。针对MDS移植后复发的预防，在预处理方案中，新增“地西他滨与其他药物(如去甲氧柔红霉素)联合使用可有效降低高危MDS患者移植后的复发率（2A类）”的Ⅱ级推荐，见下表。针对AML移植后复发的抢先治疗，在靶向药物的Ⅲ级推荐中新增“阿伐替尼（3类）”和“去甲基化药物（3类）”；在细胞免疫治疗的I级推荐中新增“改良DLI(2A类)”，见下表。针对ALL移植后复发的抢先治疗，在免疫治疗的Ⅱ级推荐中新增“贝林妥欧单抗（2A类）”，见下表。针对AML移植后复发的治疗，在免疫治疗的Ⅲ级推荐中新增“GO单抗(2A)”；在靶向治疗的Ⅱ级推荐中细化或新增“1.针对FLT3抑制剂吉瑞替尼（1类）和针对FLT3-ITD患者选择索拉非尼联合HMA（2A类）；2.IDH1抑制剂艾伏尼布、奥鲁替尼（2A类）；3.IDH2抑制剂恩西地平（2A类）”；Ⅲ级推荐中新增“2.其他如menin抑制剂(针对KMT2Ar或NPM1突变)（3类）”，见下表。09随访在移植后随访中新增“地中海贫血内容”，见下表。自体造血干细胞移植01适应证针对多发性骨髓瘤自体造血干细胞移植的适应证，将肾功能评估I级推荐中的“血30ml/min≤Cr<60ml/min且尿量正常时，预处理剂量减量(马法兰剂量减为140mg/M2)”和“血Cr<30ml/min，权衡移植利弊”分别调整为Ⅱ级、Ⅲ级推荐，见下表。专家简介许兰平教授北京大学人民医院国家血液系统疾病临床医学研究中心北京大学人民医院血液科副主任、主任医师、博导海峡两岸医药卫生交流协会第三届、第四届理事会常务理事，第二届、第三届血液学专委会主任委员中华骨髓库北京分库第三届专家委员会主任委员中国研究型医院学会细胞研究与治疗专委会常务委员中国医疗保健国际交流促进会临床微生物与感染分会委员中国造血干细胞捐献者资料库第八届、第九届专家委员会委员《白血病.淋巴瘤》《中华老年多器官杂志》《中华血液学杂志》杂志编委2014、2017位两次列国家科学技术进步奖二等奖获奖者名单主要研究方向：造血干细胞移植治疗骨髓衰竭性疾病的研究责任作者或第一作者发表SCI文章50余篇，共同作者参与发表文章500余篇，参与编写教材或论著十余次（来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

CSCO会议临床1期

2025-04-25

·ioncology

2025 ASCO大会前瞻丨血液肿瘤领域有哪些重磅研究入选？一文速览

点击蓝字关注我们编者按：2025年美国临床肿瘤学会年会（ASCO）将于美国东部时间（GMT-5）5月30日至6月3日在芝加哥召开。作为全球规模最大、学术水平最高、最具权威性的国际肿瘤会议之一，2025年ASCO年会将汇聚顶级肿瘤专家、学者和行业领袖，共探肿瘤领域的前沿研究成果和先进治疗方法。日前，2025 ASCO入选摘要标题（包括Late-Breaking Abstracts）已发布。摘要具体内容将在2025年5月22日发布，Late-breaking摘要内容将在会议当天发布。《肿瘤瞭望-血液时讯》特别整理血液肿瘤领域的重磅研究，包括1项LBA、27项口头报告、27项快速口头报告，助力大家提前了解会议的重磅内容。01Plenary Session当地时间：6月1日13:00-16:00报告地点：Hall B1摘要号：LBA3英文标题：Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV)中文标题：：rusfertide治疗真性红细胞增多症（PV）的三期、双盲、安慰剂（PBO）对照VERIFY研究结果讲者：Andrew Tucker Kuykendall, MD| Moffitt Cancer Center02Oral Abstract Session淋巴瘤与慢性淋巴细胞白血病当地时间：5月30日14:45–17:45报告地点：S100a摘要号：7000英文标题：Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial中文标题：通过PhasED-Seq对国家试验中DLBCL患者治疗结束ctDNA MRD的前瞻性验证讲者：Steven Wang, MD | Amsterdam UMC Location Vrije Universiteit摘要号：7001英文标题：Revision of staging system for natural killer T-cell lymphoma: A multicenter study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group中文标题：自然杀伤性 T 细胞淋巴瘤分期系统修订：中国西南肿瘤学组及亚洲淋巴瘤研究组多中心研究讲者：林桐榆（四川省肿瘤医院）摘要号：7002英文标题：Molecular landscape of distinct follicular lymphoma histologic grades: Insights from genomic and transcriptome analyses中文标题：不同组织学分级滤泡性淋巴瘤的分子图谱：来自基因组和转录组分析的见解讲者：孙聪（天津医科大学肿瘤医院）摘要号：7003英文标题：A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL)中文标题：KITE-363抗CD19/CD20嵌合抗原受体（CAR）T细胞治疗复发/难治性B细胞淋巴瘤患者的Ⅰ期临床研究讲者：Saurabh Dahiya, MD, FACP | Stanford University School of Medicine摘要号：7004英文标题：Multi-virus specific T cells to enhance the activity of bispecific antibodies in lymphoma中文标题：多病毒特异性T细胞用于增强双特异性抗体在淋巴瘤中的治疗活性讲者：Akiva Diamond, MD | Department of Medicine, Section of Hematology-Oncology, Baylor College of Medicine; Baylor St.Luke’s Medical Center; Dan L Duncan Comprehensive Cancer Center摘要号：7005英文标题：WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma中文标题：WaveLINE-003：zilovertamab vedotin联合标准治疗用于复发/难治性弥漫大B细胞淋巴瘤的Ⅱ/Ⅲ期临床试验讲者：Philippe Armand, MD, PhD | Dana-Farber Cancer Institute摘要号：7006英文标题：Sintilimab (anti-PD-1 antibody) combined with chidamide (an oral subtype-selective HDACi) followed by P-GemOx regimen in patients with treatment-naïve extranodal natural killer/T cell lymphoma (TN-ENKTL): A multicenter, open-label, single-arm, phase II study (SCENT-2 trial)中文标题：信迪利单抗（抗PD-1抗体）联合西达本胺（一种口服HDACi）继以 P-GemOx 方案治疗初治结外自然杀伤性 /T 细胞淋巴瘤（TN-ENKTL）患者的多中心、开放标签、单臂、II 期研究（SCENT-2 试验）讲者：黄慧强（中山大学肿瘤防治中心）摘要号：7007英文标题：Sintilimab (anti-PD-1) plus ifosfamide, carboplatin, and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind phase 3 study (ORIENT-21)中文标题：信迪利单抗（抗PD-1）联合依托泊苷（ICE）方案用于二线治疗经典霍奇金淋巴瘤（cHL）：一项多中心、随机、对照、双盲 III 期研究（ORIENT-21）的结果讲者：刘鹏（中国医学科学院肿瘤医院）摘要号：7008英文标题：Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203)中文标题：先天细胞接合剂acimtamig（AFM13）联合AlloNK（AB-101）治疗复发或难治性经典型霍奇金淋巴瘤的Ⅱ期临床试验剂量探索部分结果（LuminICE-203）讲者：Joseph E. Maakaron, MD | Division of Hematology, Oncology and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota白血病、骨髓增生异常综合征与异基因造血干细胞移植当地时间：6月2日15:00-18:00报告地点：S100a摘要号：6500英文标题：Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial中文标题：Ropeginterferon alfa-2b vs. anagrelide治疗原发性血小板增多症：SURPASS-ET Ⅲ期临床试验的主要结果讲者：Ruben A. Mesa, MD | Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine摘要号：6501英文标题：Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE)中文标题：asciminib（ASC）vs. nilotinib（NIL）用于新诊断慢性期慢性粒细胞白血病（CML-CP）患者的不良事件导致治疗中断时间（TTDAE）:ASC4START Ⅲb期临床试验主要终点结果讲者：Andreas Hochhaus, MD | Klinik für Innere Medizin II, Universitätsklinikum Jena摘要号：6502英文标题：Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study中文标题：CADENZA研究中pivekimab sunirine（PVEK）治疗母细胞性浆细胞样树突状细胞肿瘤（BPDCN）患者的疗效与安全性讲者：Naveen Pemmaraju, MD | The University of Texas MD Anderson Cancer Center摘要号：6503英文标题：Phase II study of cladribine, low-dose cytarabine, and venetoclax, alternating with azacitidine and venetoclax, in higher-risk chronic myelomonocytic leukemia and myelodysplastic syndromes中文标题：克拉屈滨、低剂量阿糖胞苷联合维奈克拉与阿扎胞苷联合维奈克拉交替治疗高危慢性粒单核细胞白血病和骨髓增生异常综合征的Ⅱ期临床研究讲者：Guillermo Montalban-Bravo, MD | The University of Texas MD Anderson Cancer Center摘要号：6504英文标题：An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts中文标题：全口服方案decitabine-cedazuridine（DEC-C）联合维奈克拉（VEN）用于不适合强化诱导化疗的新诊断急性髓系白血病（AML）患者：来自101例患者的Ⅱ期队列研究结果讲者：Amer Methqal Zeidan, MBBS | Yale University School of Medicine摘要号：6505英文标题：Phase 1b/2 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients (pts) with treatment-naïve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies中文标题：lisaftoclax（APG-2575）联合阿扎胞苷（AZA）治疗初治或既往接受过维奈克拉（VEN）治疗的髓系恶性肿瘤患者的Ⅰb/Ⅱ期临床研究讲者：Michael Francis Leahy, FRACP, FRCP, FRCPath, MBChB | Royal Perth Hospital摘要号：6506英文标题：Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study中文标题：Ziftomenib治疗复发/难治性（R/R）NPM1突变急性髓系白血病（AML）：关键KOMET-001研究中Ⅰb/Ⅱ期临床疗效和安全性结果讲者：Eunice S. Wang, MD | Roswell Park Comprehensive Cancer Center摘要号：6507英文标题：γ9δ2 T-cell activation (γδTCA) with ICT01 combined with azacitidine-venetoclax (AV) for older/unfit adults with newly diagnosed (ND) AML: Preliminary efficacy and dose selection in phase 1/2 study EVICTION中文标题：γ9δ2 T细胞激活（γδTCA）联合ICT01和阿扎胞苷-维奈克拉（AV）治疗高龄/unfit新诊断急性髓系白血病（AML）成年患者：EVICTION Ⅰ/Ⅱ期研究中的初步疗效和剂量选择讲者：Pierre Yves Dumas, MD, PhD| CHU摘要号：6508英文标题：Long-term outcomes of patients surviving beyond 2 years post–allogeneic stem cell transplantation中文标题：接受异基因造血干细胞移植后存活超过2年患者的长期结局讲者：Arjun Datt Law, MD, DM, MBBS, FCRP | Princess Margaret Cancer Centre浆细胞病当地时间：6月3日09:45-12:45报告地点：S100bc摘要号：7500英文标题：MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial中文标题：在适合移植的新诊断多发性骨髓瘤（NDMM）患者中，IsaKRD诱导后MRD驱动策略：MIDAS Ⅲ期临床试验的主要终点讲者：Aurore Perrot, MD, PhD | Toulouse University, CHU Oncopole摘要号：7501英文标题：Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial中文标题：皮下注射达雷妥尤单抗（Dara）+硼替佐米/来那度胺/地塞米松（VRd）联合达雷妥尤单抗+来那度胺（DR）维持治疗适合移植（TE）新诊断多发性骨髓瘤（NDMM）患者：PERSEUS Ⅲ期临床试验中持续微小残留病（MRD）阴性的分析讲者：Philippe Moreau, MD, PhD | University Hospital Hôtel-Dieu摘要号：7502英文标题：Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)中文标题：卡非佐米-来那度胺-地塞米松联合或不联合艾沙妥昔单抗（Isatuximab）治疗新诊断多发性骨髓瘤患者：Ⅲ期IsKia临床试验中的持续微小残留病（MRD）阴性分析讲者：Francesca Gay, MD, PhD | Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino摘要号：7503英文标题：Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial中文标题：卡非佐米、来那度胺和地塞米松（KRd）联合或不联合达雷妥尤单抗（D）治疗新诊断多发性骨髓瘤（NDMM）患者的随机多中心研究：ADVANCE临床试验讲者：Carl Ola Landgren, MD, PhD | Myeloma Program and Experimental Therapeutics Program, University of Miami摘要号：7504英文标题：Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1中文标题：Elranatamab联合达雷妥尤单抗和来那度胺（EDR）治疗不适合接受移植的新诊断多发性骨髓瘤（NDMM）患者：MagnetisMM-6 part 1的初步结果讲者：HANG QUACH, MD, FRACP, FRCPA | St Vincent’s Hospital Melbourne, University of Melbourne摘要号：7505英文标题：First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results中文标题：JNJ-79635322（JNJ-5322）新型三特异性抗体（TsAb）在复发/难治性多发性骨髓瘤（RRMM）患者中的首次人体研究：初步Ⅰ期结果讲者：Niels W.C.J. van de Donk, MD, PhD | Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology摘要号：7506英文标题：Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study中文标题：艾沙妥昔单抗（Isa）通过体外输送系统（OBDS）皮下（SC）给药vs. Isa静脉注射（IV），联合泊马度胺和地塞米松（Pd）治疗复发/难治性多发性骨髓瘤（RRMM）：随机非劣效性Ⅲ期IRAKLIA研究结果讲者：Xavier P. Leleu, MD, PhD | Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402摘要号：7507英文标题：Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM)中文标题：CARTITUDE-1研究中接受ciltacabtagene autoleucel（cilta-cel）治疗的复发/难治性多发性骨髓瘤（RRMM）患者的长期（≥5年）缓解与生存情况讲者：Peter M. Voorhees, MD | Atrium Health / Levine Cancer Institute, Wake Forest University School of Medicine摘要号：7508英文标题：Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201中文标题：Nexicart-2的安全性与疗效数据：CAR-T在R/R轻链淀粉样变中的首次美国试验（Nxc-201）讲者：Heather Jolie Landau, MD | Memorial Sloan Kettering Cancer Center03Rapid Oral Abstract Session白血病、骨髓增生异常综合征与异基因造血干细胞移植当地时间：5月30日13:00-14:30报告地点：E450a摘要号：6509英文标题：A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults中文标题：asciminib联合达沙替尼、泼尼松和贝林妥欧单抗治疗成人Ph阳性急性白血病的Ⅰ期临床研究讲者：Marlise R Luskin, MD | Dana-Farber Cancer Institute摘要号：6510英文标题：MRD negativity after end of induction in the phase 3 PhALLCON trial: A post hoc analysis中文标题：PhALLCON Ⅲ期临床试验中诱导治疗结束后的MRD阴性率：事后分析讲者：Ibrahim Aldoss, MD | City of Hope – Duarte摘要号：6511英文标题：Reduced dose PTCy in patients with acute myeloid leukemia receiving matched unrelated donor allogeneic hematopoietic stem cell transplantation中文标题：减量PTCy用于接受配型无关供者异基因造血干细胞移植的急性髓系白血病患者讲者：Nihar Desai, MD, DM | Princess Margaret Hospital摘要号：6512英文标题：Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)–naive patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial中文标题：COMMANDS研究中luspatercept（LUSPA）对比促红素α（epoetin alfa，EA）治疗未使用促红素治疗的极低、低或中危骨髓增生异常综合征（MDS）患者的总体生存期（OS）与获得输血独立（TI）后反应持续时间分析讲者：Guillermo Garcia-Manero, MD | University of Texas MD Anderson Cancer Center摘要号：6513英文标题：Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study中文标题：bexmarilimab联合阿扎胞苷抑制巨噬细胞检查点Clever-1治疗骨髓增生异常综合征的疗效：BEXMAB Ⅰ/Ⅱ期研究结果讲者：Naval Guastad Daver, MD | Department of Leukemia, The University of Texas MD Anderson Cancer Center摘要号：6514英文标题：Dosing decitabine and venetoclax for terminal differentiation to improve outcomes in TP53 mutant MDS and AML中文标题：地西他滨和维奈克拉用于诱导终末分化，以改善TP53突变型MDS和AML的治疗结局讲者：Mendel Goldfinger, MD | Montefiore Einstein Comprehensive Cancer Center摘要号：6515英文标题：IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF)中文标题：IMproveMF更新：imetelstat（IME）联合芦可替尼（RUX）治疗中危1（INT-1）、中危2（INT-2）或高危（HR）骨髓纤维化（MF）患者的Ⅰ/Ⅰb期临床试验讲者：John Mascarenhas, MD | Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai摘要号：6516英文标题：Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial中文标题：asciminib（ASC）治疗接受过1种酪氨酸激酶抑制剂（TKI）治疗的慢性期慢性髓性白血病（CML-CP）患者的疗效和安全性：Ⅱ期ASC2ESCALATE试验的中期分析（IA）讲者：David Jacob Andorsky, MD | Rocky Mountain Cancer Centers, US Oncology Research摘要号：6517英文标题：Age-related macular degeneration in individuals with clonal hematopoiesis中文标题：克隆性造血个体的年龄相关性黄斑变性讲者：Keishla Marie Arce-Ruiz, BS | McGraw/Patterson Center for Population Sciences, Dana-Farber Cancer Institute淋巴瘤与慢性淋巴细胞白血病当地时间：5月31日08:00-09:30报告地点：E450a摘要号：7009英文标题：Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL: Results in SEQUOIA arm D中文标题：zanubrutinib（zanu）联合维奈克拉（ven）治疗初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）：SEQUOIA研究D组结果讲者：Mazyar Shadman, MD, MPH | Fred Hutchinson Cancer Center and University of Washington摘要号：7010英文标题：Phase 1/2 studies of DZD8586 in CLL/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders中文标题：DZD8586 在经共价或非共价 BTK 抑制剂及 BTK 降解剂治疗后的 CLL/SLL 患者中的I/II期研究讲者：李建勇（江苏省人民医院）摘要号：7011英文标题：SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)中文标题：SEQUOIA研究5年随访，C组：前线zanubrutinib单药治疗del(17p)及未经治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者讲者：Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS | Alfred Hospital and Monash University摘要号：7012英文标题：A phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/refractory non-Hodgkin lymphoma中文标题：一项1/2期研究：评估选择性 EZH2 抑制剂 XNW5004 在复发/难治性非霍奇金淋巴瘤患者中的安全性与有效性讲者：邱录贵[中国医学科学院血液病医院（中国医学科学院血液学研究所）]摘要号：7013英文标题：CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study中文标题：以 CD79b 为靶点的抗体偶联药物（ADC）SHR - A1912 联合R - GemOx方案用于复发 / 难治性（R/R）弥漫性大 B 细胞淋巴瘤（DLBCL）患者的1b/2期研究数据讲者：李亚军（湖南省肿瘤医院）摘要号：7014英文标题：Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): Interim results from the phase II MorningSun study中文标题：固定疗程皮下（SC）莫妥珠单抗（Mosun）治疗既往未治疗的高肿瘤负担滤泡性淋巴瘤（FL）患者：Ⅱ期MorningSun研究的中期结果讲者：Ian W. Flinn, MD, PhD | Tennessee Oncology and OneOncology摘要号：7015英文标题：Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO中文标题：格菲妥单抗联合吉西他滨和奥沙利铂（Glofit-GemOx）治疗复发/难治性（R/R）弥漫大B细胞淋巴瘤（DLBCL）患者：STARGLO研究2年随访结果讲者：Jeremy S. Abramson, MD | Massachusetts General Hospital Cancer Center摘要号：7016英文标题：Worldwide experience of chronic active EBV infection: Retrospective cohort study中文标题：全球慢性活动性EBV感染经验：回顾性队列研究讲者：王欣然（华中科技大学同济医学院附属同济医院）摘要号：7017英文标题：Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study中文标题：伊布替尼联合维奈克拉一线治疗年龄较大或存在TP53突变的套细胞淋巴瘤（MCL）患者的疗效和安全性：SYMPATICO研究讲者：Michael Wang, MD | Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center创新性治疗—免疫疗法当地时间：6月1日11:15-12:45报告地点：S406摘要号：2514英文标题：Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL)中文标题：靶向CCR8抗体治疗复发/难治性皮肤T细胞淋巴瘤（R/R CTCL）的Ⅰ期临床试验剂量递增阶段初步结果讲者：李志铭（中山大学肿瘤防治中心）浆细胞病当地时间：6月2日08:00-09:30报告地点：E450b摘要号：7509英文标题：Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for high-risk (HR) newly diagnosed multiple myeloma (NDMM): First-time report of the full cohort of transplant-eligible (TE) patients in the GMMG-CONCEPT trial中文标题：艾沙妥昔单抗、卡非佐米、来那度胺和地塞米松（Isa-KRd）治疗高危（HR）新诊断多发性骨髓瘤（NDMM）：GMMG-CONCEPT研究中适合移植（TE）患者全队列的首次报告讲者：Lisa B. Leypoldt, MD | University Medical Center Hamburg-Eppendorf摘要号：7510英文标题：Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial中文标题：Linvoseltamab（LINVO）联合硼替佐米（BTZ）治疗复发/难治性多发性骨髓瘤（RRMM）患者：LINKER-MM2研究的首次结果讲者：Xavier P. Leleu, MD, PhD | Hematology, CIC 1082, U1313, CHU, University摘要号：7511英文标题：Heterogeneity in the expression of GPRC5D between patients with multiple myeloma中文标题：多发性骨髓瘤患者中GPRC5D表达的异质性讲者：Harsh Parmar | John Theurer Cancer Center, Hackensack University Medical Center摘要号：7512英文标题：Belantamab mafodotin plus lenalidomide/dexamethasone in newly diagnosed intermediate-fit & frail multiple myeloma patients: Long-term efficacy and safety from the phase 1/2 BELARD clinical trial中文标题：Belantamab mafodotin联合来那度胺/地塞米松治疗新诊断的中度fit和虚弱多发性骨髓瘤患者：来自Ⅰ/Ⅱ期BELARD临床试验的长期疗效和安全性结果讲者：Evangelos Terpos, MD, PhD | Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine摘要号：7513英文标题：Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial中文标题：Linvoseltamab（LINVO）联合卡非佐米（CFZ）治疗复发/难治性多发性骨髓瘤（RRMM）患者：LINKER-MM2研究的初步结果讲者：Salomon Manier, MD, PhD | Hematology Department, Lille University Hospital摘要号：7514英文标题：Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results中文标题：ISB 2001的Ⅰ期首次人体研究：一种针对BCMAxCD38xCD3的三特异性抗体治疗复发/难治性多发性骨髓瘤（RRMM）患者——剂量递增（DE）结果讲者：Eben I. Lichtman, MD | UNC Lineberger Comprehensive Cancer Center摘要号：7515英文标题：Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial中文标题：belantamab mafodotin联合泊马度胺和地塞米松（BPd）与泊马度胺、硼替佐米和地塞米松（PVd）治疗复发/难治性多发性骨髓瘤（RRMM）患者的微小残留病（MRD）阴性率比较：来自DREAMM-8研究的分析讲者：Suzanne Trudel, MD | Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre摘要号：7516英文标题：Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study中文标题：达雷妥尤单抗联合硼替佐米、来那度胺和地塞米松（DVRd）治疗新诊断多发性骨髓瘤（NDMM）患者：Ⅲ期CEPHEUS研究中不适合移植（TIE）患者的亚组分析讲者：Saad Z Usmani, MD, MBA, FRCP, FASCO | Memorial Sloan Kettering Cancer Center（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果ASCO会议临床1期细胞疗法免疫疗法

100 项与地西他滨相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03665	地西他滨	L01BC08	DB01262

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性髓性白血病	欧盟	Janssen-Cilag International NV	2012-09-20
急性髓性白血病	冰岛	Janssen-Cilag International NV	2012-09-20
急性髓性白血病	列支敦士登	Janssen-Cilag International NV	2012-09-20
急性髓性白血病	挪威	Janssen-Cilag International NV	2012-09-20
难治性贫血	美国	Otsuka Pharmaceutical Co., Ltd.	2006-05-02
难治性贫血伴原始细胞过多	美国	Otsuka Pharmaceutical Co., Ltd.	2006-05-02
慢性粒单核细胞白血病	美国	Otsuka Pharmaceutical Co., Ltd.	2006-05-02
难治性血细胞减少伴多系发育不良和环状铁粒幼细胞	美国	Otsuka Pharmaceutical Co., Ltd.	2006-05-02
骨髓增生异常综合征	美国	Otsuka Pharmaceutical Co., Ltd.	2006-05-02

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
成人急性髓性白血病	临床3期	-	西安杨森制药有限公司	2012-05-01
复发性急性髓细胞白血病	临床3期	美国	Eisai, Inc.	2006-08-01
晚期三阴性乳腺癌	临床2期	美国	Merck Sharp & Dohme Corp.	2017-01-24
3型乳腺癌	临床2期	美国	Merck Sharp & Dohme Corp.	2017-01-24
ER阳性乳腺癌	临床2期	美国	Merck Sharp & Dohme Corp.	2017-01-24
ER阴性乳腺癌	临床2期	美国	Merck Sharp & Dohme Corp.	2017-01-24
HER2 阴性乳腺癌	临床2期	美国	Merck Sharp & Dohme Corp.	2017-01-24
浸润性乳腺癌	临床2期	美国	Merck Sharp & Dohme Corp.	2017-01-24
局部晚期乳腺癌	临床2期	美国	Merck Sharp & Dohme Corp.	2017-01-24
孕激素受体阳性肿瘤	临床2期	美国	Merck Sharp & Dohme Corp.	2017-01-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AACR2025	N/A	-	-	decitabine (PCIF1 overexpression)	蓋廠積繭蓋獵製廠醖鬱(製鬱壓觸膚構獵醖遞鹽) = significant 憲蓋衊鑰膚簾襯選築醖 (選鬱選簾選衊願醖獵簾 ) 更多	积极	2025-04-28
NCT02957968 (Pubmed \| J Immunother Cancer)	临床2期	HER2 阴性乳腺癌新辅助 TILs \| PD-L1	46	Decitabine + Pembrolizumab	鹹壓襯選選艱鑰網鏇淵(觸鏇餘糧膚窪憲鏇獵觸) = 鹹憲鑰鏇觸夢簾製網製願糧鏇構蓋選選憲鹹鏇 (醖夢鹹觸憲繭製淵餘艱 ) 更多	积极	2025-02-01
NCT02957968 (Pubmed \| J Immunother Cancer)	临床2期	HER2 阴性乳腺癌新辅助 TILs \| PD-L1	46	Standard Neoadjuvant Chemotherapy	鹹壓襯選選艱鑰網鏇淵(觸鏇餘糧膚窪憲鏇獵觸) = 鬱鏇淵齋窪構鹹積齋憲願糧鏇構蓋選選憲鹹鏇 (醖夢鹹觸憲繭製淵餘艱 ) 更多	积极	2025-02-01
NCT05222984 (ASH2024)	临床1期	急性髓性白血病	-	Navitoclax/Venetoclax/Decitabine Combination	膚遞齋製鏇餘襯範襯廠(鑰簾簾衊醖網糧選選構) = 壓願選夢齋築淵鹽壓艱鬱遞淵襯獵觸襯構糧糧 (淵願願醖憲餘淵顧繭襯 )	-	2024-12-09
ASH2024	N/A	骨髓增生异常综合征	-	Oral Decitabine and Cedazuridine (DEC-C)	膚鏇願願鬱願憲範獵鑰(繭蓋壓鹹鬱襯鏇衊憲範) = 鏇醖鑰糧築鹹繭觸簾膚鹹鹹鹹齋顧淵窪鹹齋鑰 (鹹選鬱蓋衊獵鹹餘鏇夢 ) 更多	-	2024-12-09
ASH2024	N/A	骨髓增生异常综合征	-	Intravenous/Subcutaneous Hypomethylating Agents (IV/SC HMA)	膚鏇願願鬱願憲範獵鑰(繭蓋壓鹹鬱襯鏇衊憲範) = 淵淵繭鹽憲衊網餘糧鹽鹹鹹鹹齋顧淵窪鹹齋鑰 (鹹選鬱蓋衊獵鹹餘鏇夢 ) 更多	-	2024-12-09
ASH2024	N/A	-	-	Venetoclax	製壓窪觸鬱鏇鏇衊壓顧(衊醖築衊築鹹製齋蓋齋) = common adverse reactions including febrile neutropenia 艱鏇範淵簾遞繭憲鏇製 (衊夢鹹鹹餘築鹹鑰獵遞 ) 更多	-	2024-12-09
2898Venetoclax (ASH2024)	临床1/2期	急性髓性白血病	40	Venetoclax + D-CAG regimen	觸製繭願窪願構獵糧憲(夢醖選蓋製膚積夢壓積) = 憲鏇獵範齋鬱襯衊衊艱膚鹹獵觸廠獵襯鹽觸遞 (範繭醖艱願範繭鏇積壓 ) 更多	积极	2024-12-08
ASH2024	N/A	急性髓性白血病	-	DCAG+UCB-MST+IL-2	醖齋簾醖構憲製鏇窪壓(餘遞鏇鹹顧餘範艱蓋築) = 糧鬱廠構顧膚鑰構築糧壓積顧積網壓膚齋醖鹽 (範鏇鑰鏇選鏇選鏇積鬱 ) 更多	-	2024-12-07
ASH2024	N/A	急性髓性白血病	-	DCAG	醖齋簾醖構憲製鏇窪壓(餘遞鏇鹹顧餘範艱蓋築) = 獵網壓築鹽積夢鹹鏇獵壓積顧積網壓膚齋醖鹽 (範鏇鑰鏇選鏇選鏇積鬱 ) 更多	-	2024-12-07
ASH2024	N/A	伴有 11q23 异常的急性髓系白血病	-	Intensified conditioning containing Decitabine	鏇膚糧網廠艱積鏇襯憲(鑰齋選構鹹積艱淵夢築) = 1 (1.0%) patient in the intensified group died of heart toxicity 願淵願簾網蓋遞餘遞蓋 (製憲壓繭憲繭鬱鑰夢餘 ) 更多	-	2024-12-07
ASH2024	N/A	伴有 11q23 异常的急性髓系白血病	-	Decitabine (Standard myeloablative conditioning)		-	2024-12-07
SOHO2024	N/A	复发性急性髓细胞白血病	-	Decitabine	觸願壓製鏇選積艱衊壓(廠鑰顧遞廠壓壓獵鏇衊) = reported by the patient 繭衊製簾蓋簾網選淵鏇 (鏇鏇鏇蓋艱願鑰廠艱觸 ) 更多	-	2024-09-04
NCT04188405 (Pubmed \| Lancet Haematol) 人工标引	临床2期	慢性期慢性髓性白血病 \| 费城染色体阳性急性髓性白血病	20	Decitabine, venetoclax, and ponatinib	淵窪艱壓齋糧簾鏇觸鑰(鹹齋夢鑰選鹽構觸艱襯) = 襯範鑰簾壓鹽簾築餘網鹹獵齋衊繭選製築襯鏇 (窪製鑰壓膚壓衊壓範蓋 ) 更多	积极	2024-09-01